English version of Japanese guidance for use of biologics for psoriasis (the 2022 version)
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
English version of Japanese guidance for use of biologics for psoriasis (the 2022 version)
Authors
Keywords
-
Journal
JOURNAL OF DERMATOLOGY
Volume 50, Issue 2, Pages -
Publisher
Wiley
Online
2022-12-30
DOI
10.1111/1346-8138.16691
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety of Brodalumab in Plaque Psoriasis: Integrated Pooled Data from Five Clinical Trials
- (2022) Kristian Reich et al. ACTA DERMATO-VENEREOLOGICA
- Adalimumab with methotrexate versus adalimumab monotherapy in psoriasis: First-year results of a single-blind randomized controlled trial
- (2022) G.E. van der Kraaij et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Long‐term efficacy and safety of brodalumab in moderate‐to‐severe plaque psoriasis: a post hoc pooled analysis of AMAGINE‐2 and ‐3
- (2022) K. Reich et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021
- (2022) Laura C. Coates et al. Nature Reviews Rheumatology
- IL‐17 inhibitors and inflammatory bowel diseases: a post‐marketing study in Vigibase®
- (2021) Nadine Petitpain et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Five‐year efficacy and safety of tildrakizumab in patients with moderate to severe psoriasis who respond at week 28: pooled analyses of two randomised phase 3 clinical trials (reSURFACE 1 and reSURFACE 2)
- (2021) D. Thaçi et al. BRITISH JOURNAL OF DERMATOLOGY
- Are biologics combined with methotrexate better than biologics monotherapy in psoriasis and psoriatic arthritis: a meta‐analysis of randomized controlled trials
- (2021) Yan Xie et al. Dermatologic Therapy
- Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64‐week phase 3 study (reSURFACE 1)
- (2021) Atsuyuki Igarashi et al. JOURNAL OF DERMATOLOGY
- Long‐term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5‐year extension of a phase 3 study (reSURFACE 1)
- (2021) Shinichi Imafuku et al. JOURNAL OF DERMATOLOGY
- Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial
- (2021) Kristian Reich et al. LANCET
- Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial
- (2021) Kenneth B Gordon et al. LANCET
- Bimekizumab versus Adalimumab in Plaque Psoriasis
- (2021) Richard B. Warren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bimekizumab versus Secukinumab in Plaque Psoriasis
- (2021) Kristian Reich et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: 52-Week Results
- (2021) Yoshinori Umezawa et al. Dermatology and Therapy
- Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): A Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Reported Data from the BE RADIANT Phase 3b Trial
- (2021) Alice B. Gottlieb et al. ADVANCES IN THERAPY
- Gastroenterological safety of IL-17 inhibitors: a systematic literature review
- (2021) Bénédicte Caron et al. Expert Opinion On Drug Safety
- Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial
- (2021) Lars Erik Kristensen et al. ANNALS OF THE RHEUMATIC DISEASES
- Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: Effect of Demographics and Baseline Disease Characteristics on Efficacy
- (2021) Shinichi Imafuku et al. Dermatology and Therapy
- Japanese guidance for use of biologics for psoriasis (the 2019 version)
- (2020) Hidehisa Saeki et al. JOURNAL OF DERMATOLOGY
- JOINT AAD-NPF GUIDELINES OF CARE FOR THE MANAGEMENT OF PSORIASIS WITH SYSTEMIC NON-BIOLOGICAL THERAPIES
- (2020) Alan Menter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Japan Society of Hepatology guidelines for the management of hepatitis C virus infection: 2019 update
- (2020) HEPATOLOGY RESEARCH
- Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
- (2020) Philip J Mease et al. LANCET
- Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial
- (2020) Iain B McInnes et al. LANCET
- EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
- (2020) Laure Gossec et al. ANNALS OF THE RHEUMATIC DISEASES
- Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52
- (2020) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Time to relapse after tildrakizumab withdrawal in patients with moderate‐to‐severe psoriasis who were responders at week 28: post‐hoc analysis through 64 weeks from reSURFACE 1 trial
- (2020) R.B. Warren et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52‐week results from a Phase 3 double‐blind randomised, controlled trial
- (2020) C. Bodemer et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Blockade of the IL-17 signaling pathway increased susceptibility of psoriasis patients to superficial fungal infections
- (2020) Junichiro Hiruma et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Secukinumab and ustekinumab treatment in psoriatic arthritis: results of a direct comparison
- (2020) Jean-Guillaume Letarouilly et al. RHEUMATOLOGY
- Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study
- (2020) Josef S. Smolen et al. Rheumatology and Therapy
- Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
- (2019) Alan Menter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (re SURFACE 1 and re SURFACE 2) through 148 weeks
- (2019) K. Reich et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial
- (2019) Mamitaro Ohtsuki et al. JOURNAL OF DERMATOLOGY
- Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial
- (2019) Kristian Reich et al. LANCET
- Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate‐to‐severe psoriasis: a pooled analysis of two randomized controlled trials
- (2019) A. Blauvelt et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis
- (2018) A. Egeberg et al. BRITISH JOURNAL OF DERMATOLOGY
- Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study
- (2018) Shigetoshi Sano et al. JOURNAL OF DERMATOLOGY
- Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study
- (2018) Mamitaro Ohtsuki et al. JOURNAL OF DERMATOLOGY
- Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)
- (2018) R. Bissonnette et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study
- (2018) Atul Deodhar et al. LANCET
- Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
- (2018) Kenneth B Gordon et al. LANCET
- Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch
- (2017) Mamitaro Ohtsuki et al. JOURNAL OF DERMATOLOGY
- Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)
- (2017) Désirée van der Heijde et al. JOURNAL OF RHEUMATOLOGY
- Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study
- (2017) Kim Papp et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
- (2017) Peter Nash et al. LANCET
- Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
- (2017) Kristin K Jørgensen et al. LANCET
- Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study
- (2017) Iain B McInnes et al. RHEUMATOLOGY
- Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
- (2016) Philip J Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study
- (2016) K. Yamasaki et al. BRITISH JOURNAL OF DERMATOLOGY
- A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis
- (2016) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Use of Apremilast in Combination With Other Therapies for Treatment of Chronic Plaque Psoriasis
- (2016) Mohn’d AbuHilal et al. JOURNAL OF CUTANEOUS MEDICINE AND SURGERY
- Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study
- (2016) Hidemi Nakagawa et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J)
- (2016) Hidehisa Saeki et al. JOURNAL OF DERMATOLOGY
- Efficacy and safety of dose escalation of infliximab therapy in Japanese patients with psoriasis: Results of the SPREAD study
- (2016) Hideshi Torii et al. JOURNAL OF DERMATOLOGY
- Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study
- (2016) Shinichi Imafuku et al. JOURNAL OF DERMATOLOGY
- Safety and efficacy of adalimumab treatment in Japanese patients with psoriasis: Results of SALSA study
- (2016) Akihiko Asahina et al. JOURNAL OF DERMATOLOGY
- Long-term clinical safety and efficacy of brodalumab in the treatment of Japanese patients with moderate-to-severe plaque psoriasis
- (2016) Y. Umezawa et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
- (2016) Kenneth B. Gordon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adalimumab treatment optimization for psoriasis: Results of a long-term phase 2/3 Japanese study
- (2015) Akihiko Asahina et al. JOURNAL OF DERMATOLOGY
- Safety profiles and efficacy of infliximab therapy in Japanese patients with plaque psoriasis with or without psoriatic arthritis, pustular psoriasis or psoriatic erythroderma: Results from the prospective post-marketing surveillance
- (2015) Hideshi Torii et al. JOURNAL OF DERMATOLOGY
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
- (2015) Diamant Thaçi et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)
- (2015) Ulrich Mrowietz et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Iain B McInnes et al. LANCET
- Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
- (2015) Mark Lebwohl et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis
- (2015) Kenneth B. Gordon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
- (2015) Philip J. Mease et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up
- (2014) Erik H Vogelzang et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
- (2014) Christopher Ritchlin et al. ANNALS OF THE RHEUMATIC DISEASES
- Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials
- (2014) Arthur Kavanaugh et al. ANNALS OF THE RHEUMATIC DISEASES
- Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: Subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study
- (2014) Mamitaro Ohtsuki et al. JOURNAL OF DERMATOLOGY
- Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis
- (2014) Ryuji Koike et al. Modern Rheumatology
- Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis
- (2014) Philip J. Mease et al. NEW ENGLAND JOURNAL OF MEDICINE
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
- (2014) Richard G. Langley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol
- (2013) D van der Heijde et al. ANNALS OF THE RHEUMATIC DISEASES
- Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)
- (2013) P J Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study
- (2013) Karen Minde Fagerli et al. ANNALS OF THE RHEUMATIC DISEASES
- Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up
- (2013) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Japanese guidance for use of biologics for psoriasis (the 2013 version)
- (2013) Mamitaro Ohtsuki et al. JOURNAL OF DERMATOLOGY
- Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
- (2013) Iain B McInnes et al. LANCET
- Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study
- (2012) K. Papp et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study
- (2012) A.B. Kimball et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial
- (2011) Atsuyuki IGARASHI et al. JOURNAL OF DERMATOLOGY
- Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial
- (2010) Hideshi Torii et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Long-term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma
- (2010) Hideshi TORII et al. JOURNAL OF DERMATOLOGY
- Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study
- (2010) Akihiko ASAHINA et al. JOURNAL OF DERMATOLOGY
- British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009
- (2009) C.H. Smith et al. BRITISH JOURNAL OF DERMATOLOGY
- Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial
- (2009) Alice Gottlieb et al. LANCET
- Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)
- (2008) P J Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
- (2008) Craig L Leonardi et al. LANCET
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
- (2008) Kim A Papp et al. LANCET
- Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
- (2007) Alan Menter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now